Download MendeleyDiscovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods.
Pelz, N.F., Bian, Z., Zhao, B., Shaw, S., Tarr, J.C., Belmar, J., Gregg, C., Camper, D.V., Goodwin, C.M., Arnold, A.L., Sensintaffar, J.L., Friberg, A., Rossanese, O.W., Lee, T., Olejniczak, E.T., Fesik, S.W.(2016) J Med Chem 59: 2054-2066
- PubMed: 26878343 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1021/acs.jmedchem.5b01660
- Primary Citation Related Structures:
5FC4, 5FDO, 5FDR - PubMed Abstract:
Myeloid cell leukemia-1 (Mcl-1) is a member of the Bcl-2 family of proteins responsible for the regulation of programmed cell death. Amplification of Mcl-1 is a common genetic aberration in human cancer whose overexpression contributes to the evasion of apoptosis and is one of the major resistance mechanisms for many chemotherapies. Mcl-1 mediates its effects primarily through interactions with pro-apoptotic BH3 containing proteins that achieve high affinity for the target by utilizing four hydrophobic pockets in its binding groove. Here we describe the discovery of Mcl-1 inhibitors using fragment-based methods and structure-based design. These novel inhibitors exhibit low nanomolar binding affinities to Mcl-1 and >500-fold selectivity over Bcl-xL. X-ray structures of lead Mcl-1 inhibitors when complexed to Mcl-1 provided detailed information on how these small-molecules bind to the target and were used extensively to guide compound optimization.
- Department of Biochemistry, Vanderbilt University School of Medicine , 2215 Garland Avenue, 607 Light Hall, Nashville, Tennessee 37232-0146, United States.
Organizational Affiliation:
